PLx Pharma 
Welcome,         Profile    Billing    Logout  
 4 Products   0 Diseases   4 Products   1 Trial   491 News 


123»
  • ||||||||||  Locilex (pexiganan acetate) / PLx Pharma
    Review, Journal:  Strategies adopted by gastric pathogen Helicobacter pylori for a mature biofilm formation: Antimicrobial peptides as a visionary treatment. (Pubmed Central) -  Jun 3, 2023   
    To our knowledge, this review is the first of its kind to explain briefly the journey of H. pylori starting with the chemotaxis, the mechanism for selecting the site for colonization, the stress faced by the pathogen, and various adaptations to evade these stress conditions by forming biofilm and the morphological changes acquired by the pathogen in mature biofilm. Furthermore, we have explained the human GI tract antimicrobial peptides and the reason behind the failure of these AMPs, and how encapsulation of Pexiganan-A(MSI-78A) in a chitosan microsphere increases the efficiency of eradication.
  • ||||||||||  omiganan (CLS001) / Maruho, Locilex (pexiganan acetate) / PLx Pharma
    Review, Journal:  Rational design of stapled antimicrobial peptides. (Pubmed Central) -  May 1, 2023   
    P3
    Antimicrobial peptides under clinical trial: Pexiganan (NCT01594762, 2012-05-07). Omiganan (NCT02576847, 2015-10-13).
  • ||||||||||  Locilex (pexiganan acetate) / PLx Pharma
    Journal:  Peptide Flexibility and the Hydrophobic Moment are Determinants to Evaluate the Clinical Potential of Magainins. (Pubmed Central) -  Apr 25, 2023   
    The flexibility of another magainin analog (MSI-78) is even greater than that of Mag-2...Such characteristics are key to understanding the broad-spectrum antimicrobial actions exhibited by this peptide. These data reinforce the hypothesis on the determinant role of spontaneous membrane curvature, intrinsic peptide flexibility, and specific hydrophobic moment in assessing the bioactivity of membrane-active antimicrobial peptides.
  • ||||||||||  Locilex (pexiganan acetate) / PLx Pharma
    Journal:  The Impact of Antimicrobial Peptides on the Acinetobacter baumannii Inner Membrane Is Modulated by Lipid Polyunsaturation. (Pubmed Central) -  Apr 17, 2023   
    Using coarse-grained molecular dynamics simulations of complex A. baumannii inner membrane models derived from lipidomes of bacteria grown in the presence and absence of PUFAs, we examine the impact of the adsorption of four prototypical AMPs (CAMEL, LL-37, pexiganan, and magainin-2) on the membrane biophysical properties...The changes to the membrane biophysical properties also showed a complex relationship with the AMP's physical properties, such as AMP charge, chain length, and charge-to-mass ratio. Cumulatively, this work highlights the importance of studying AMPs using a complex membrane environment and provides insights into the mechanistic action of AMPs in polyunsaturated lipid-rich bacterial membranes.
  • ||||||||||  Locilex (pexiganan acetate) / PLx Pharma Inc
    Journal:  Evaluation of the efficacy of the antimicrobial peptide HJH-3 in chickens infected with Salmonella Pullorum. (Pubmed Central) -  Feb 11, 2023   
    The prevention of infection by HJH-3 was similar to that by Ampicillin; the effect of treatment after infection was lower than that of treatment before infection, and the survival rate of infected chicks treated with HJH-3 was 70%, which was still higher than that of the infected chickens. These results suggest that HJH-3 has good clinical application potential and can be used as a substitute for antibiotics for the prevention and treatment of S. Pullorum infection.
  • ||||||||||  Locilex (pexiganan acetate) / PLx Pharma Inc
    Journal:  Antimicrobial peptide-grafted PLGA-PEG nanoparticles to fight bacterial wound infections. (Pubmed Central) -  Dec 3, 2022   
    NPs are functionalized with MSI-78(4-20), an equipotent and more selective derivative of MSI-78, grafted through a thiol-maleimide (Mal) Michael addition...Furthermore, NPs do not demonstrate signs of cytotoxicity at MIC concentrations. Overall, this promising formulation helps unleash the full potential of AMPs for the management of wound infections.
  • ||||||||||  Vazalore (aspirin-PC) / PLx Pharma
    Journal:  Development of the PC-NSAID technology: from contact angle to Vazalore®. (Pubmed Central) -  Oct 22, 2022   
    Finally, we discuss the commercialization and launch of Aspirin-PC, an over-the-counter (OTC) drug with the brand name Vazalore®. Teaser: We review the development, from bench experiments to clinical trials, of the first FDA-approved phosphatidylcholine (PC)-associated NSAID, Aspirin-PC, which was launched under the brand name Vazalore® in August 2021.
  • ||||||||||  Locilex (pexiganan acetate) / PLx Pharma Inc
    Journal:  Formulation and Biological Evaluation of Mesoporous Silica Nanoparticles Loaded with Combinations of Sortase A Inhibitors and Antimicrobial Peptides. (Pubmed Central) -  May 30, 2022   
    A resazurin-modified minimum inhibitory concentration (MIC) and checkerboard assays, to measure SrtAI synergy in combination with leading antimicrobial peptides (AMPs; pexiganan (PEX), indolicidin (INDO), and [I5, R8] mastoparan (MASTO)), were determined against methicillin-sensitive (MSSA) and methicillin-resistant (MRSA) Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa...These combinations also reduced each components' toxicity against human embryonic kidney cells. In conclusion, MCM-41 MSNs provide a platform to enhance SrtAI solubility and demonstrated antimicrobial synergy with AMPs and reduced toxicity, providing novel superbug treatment opportunities.
  • ||||||||||  Vazalore (aspirin-PC) / PLx Pharma
    Journal:  Vazalore - A new aspirin formulation. (Pubmed Central) -  May 3, 2022   
    Croslinked 90/10 PVA/CA mats were deemed the most promising combination due to their moderate hydrophilicity and permeabilities, swelling capacity, and high yields of peptide loading. No abstract available
  • ||||||||||  Vazalore (aspirin-PC) / PLx Pharma
    Trial completion:  Pharmacodynamic and Pharmacokinetic Study of PL-ASA (clinicaltrials.gov) -  Apr 25, 2022   
    P4,  N=36, Completed, 
    No abstract available Active, not recruiting --> Completed
  • ||||||||||  Locilex (pexiganan acetate) / PLx Pharma Inc
    Review, Journal:  Antimicrobial Peptide Mechanisms Studied by Whole-Cell Deuterium NMR. (Pubmed Central) -  Apr 9, 2022   
    This review focusses on what can be learned about AMP mechanisms from solid-state NMR of AMP-treated intact bacteria. It also touches on flow cytometry as a complementary method for measuring permeabilization of bacterial lipid membranes in whole bacteria.
  • ||||||||||  aspirin / Generic mfg.
    PK/PD data, Review, Journal:  Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation. (Pubmed Central) -  Apr 6, 2022   
    It is associated with reduced local acute GI injury compared with plain aspirin, and predictable absorption resulting in more reliable platelet inhibition compared with enteric-coated tablets. This review explores the rationale and pharmacologic profile of PL-ASA intended to address the unmet needs for aspirin therapy.
  • ||||||||||  Locilex (pexiganan acetate) / PLx Pharma Inc
    Journal:  Systematic comparison of activity and mechanism of antimicrobial peptides against nosocomial pathogens. (Pubmed Central) -  Mar 4, 2022   
    This study demonstrated a structure and activity guidance for further design of Pardaxin (1-22) and MSI-78 (4-20) as therapeutics against MDR pathogens. The different effects of DMPC (1-19) and Cecropin B (1-21) on membrane integrity and phospholipid membrane interactions provided critical information for the rational design of next-generation analogues with specificity against either Gram-negative or Gram-positive bacteria.
  • ||||||||||  Locilex (pexiganan acetate) / PLx Pharma Inc
    Preclinical, Journal:  In vitro activity of the antimicrobial peptides h-Lf1-11, MSI-78, LL-37, fengycin 2B, and magainin-2 against clinically important bacteria. (Pubmed Central) -  Mar 3, 2022   
    The h-Lf1-11, magainin-2, and LL-37 exhibited moderate activity (MIC range of 40-160, 80-160, and 40-160 mg/L, respectively) while the fengycin 2B did not show significant activity against all bacterial strains tested. These results revealed that MSI-78, h-Lf1-11, magainin-2, and LL-37 have great potential as antibacterial agents and their activity deserves to be more explored in further studies for the treatment of antibiotic-resistant bacteria.
  • ||||||||||  Locilex (pexiganan acetate) / PLx Pharma Inc
    Journal:  Anti-Pythium insidiosum activity of MSI-78, LL-37, and magainin-2 antimicrobial peptides. (Pubmed Central) -  Mar 3, 2022   
    Antimicrobial peptides were tested against Pythium insidiosum, a microorganism that causes a difficult-to-treat disease in animals and humans. These peptides have been shown to be able to kill P. insidiosum and may be candidates for use in the treatment of this infection.
  • ||||||||||  aspirin / Generic mfg.
    PK/PD data, Journal:  The Influence of Lipid Excipients on Platelet Function and the Pharmacodynamic Effects of Aspirin. (Pubmed Central) -  Feb 2, 2022   
    The excipients did not activate platelets in the absence of agonist and did not alter activation of platelets in response to adenosine diphosphate, arachidonic acid, thrombin, or convulxin (a collagen mimetic). Lipid excipients used in an oral formulation of aspirin do not impair the pharmacodynamic effects of aspirin and do not alter platelet function.
  • ||||||||||  Locilex (pexiganan acetate) / PLx Pharma Inc
    Journal:  Grafting MSI-78A onto chitosan microspheres enhances its antimicrobial activity. (Pubmed Central) -  Jan 27, 2022   
    MSI-78A (Pexiganan A) is one of the few antimicrobial peptides (AMPs) able to kill Helicobacter pylori, a pathogenic bacterium that colonizes the gastric mucosa of half of the world's population...pylori activity even at acidic pH (gastric settings). These results highlight the strong potential of AMP-ChMic as an antibiotic alternative for H. pylori eradication.
  • ||||||||||  Vazalore (aspirin-PC) / PLx Pharma
    Enrollment closed, Trial completion date:  Pharmacodynamic and Pharmacokinetic Study of PL-ASA (clinicaltrials.gov) -  Sep 23, 2021   
    P4,  N=36, Active, not recruiting, 
    The use of AMPs combined with amphotericin B and voriconazole antifungals has great synergistic potential and deserve to be evaluated in murine models of fusariosis. Not yet recruiting --> Active, not recruiting | Trial completion date: Aug 2021 --> Oct 2021